A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

With its dwindling cash reserves set to run out this month, Windtree Therapeutics had looked like it was struggling to hold ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Scribe Therapeutics is slimming down its workforce by 20% as it readies its cardiometabolic pipeline for the clinic, a ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

Roche's Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. | Roche's Chugai Chugai ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation ...

Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...